Lipid nanoparticles — neoantigen vaccine coverage

AI / Methods

A novel bivalent neoantigen vaccine based on mRNA-loaded lipid nanoparticles eradicates hepatocellular carcinoma in mice.

Researchers developed a bivalent mRNA-LNP vaccine targeting AFP and GPC3 neoantigens for hepatocellular carcinoma (HCC). Using spleen-homing CL15H6 LNPs, the formulation achieved superior antigen presentation and co-stimulatory molecule expression on splenic dendritic cells compared to clinical standards. In mouse models, two doses provided complete prophylactic protection against HCC challenge, demonstrating high biosafety and potent cytotoxic T lymphocyte responses.

europepmc · brief 2026-07-15 · published 2026-07-13

AI / Methods

AI-Informed neoantigen prioritization enables a multi-epitope mRNA/LNP vaccine with antigen-specific immunogenicity and antitumor activity

Personalized neoantigen vaccines are an emerging strategy for cancer immunotherapy, but their effectiveness depends on selecting tumor-specific antigens capable of inducing functional T-cell responses. The VACINUS AI-informed neoantigen prioritization framework previously identif…

biorxiv · brief 2026-07-11 · published 2026-07-10

Clinical

A Single-Arm, Open-Label, Prospective Study Evaluating the Safety, Tolerability, and Immunogenicity of the NeoOVIV Vaccine in Patients With Ovarian Cancer After Surgery

West China Hospital has registered a Phase I, single-arm, open-label dose-escalation study for NeoOVIV in stage II/III ovarian cancer patients post-surgery. The personalized mRNA-lipid nanoparticle vaccine will be administered with standard adjuvant chemotherapy and a PD-1 antibody to evaluate safety, tolerability, immunogenicity, and preliminary clinical activity.

clinicaltrials · brief 2026-06-30 · published 2026-06-30

Clinical

Safety and Tolerability of AI-Designed Pan-Cancer Neoantigen mRNA Vaccine (PAN-NeoVax) in Advanced Solid Tumors

West China Hospital is recruiting for a Phase 1 study of PAN-NeoVax, an AI-designed pan-cancer neoantigen mRNA vaccine delivered via lipid nanoparticles. Administered intratumorally in patients with advanced solid tumors who have failed second-line therapy, the trial uses a classical 3+3 dose-escalation design to evaluate safety and preliminary anti-tumor efficacy.

clinicaltrials · brief 2026-06-08 · published 2026-05-11

Clinical

Safety and Tolerability of AI-Designed Pan-Cancer Neoantigen mRNA Vaccine (PAN-NeoVax) in Advanced Solid Tumors

West China Hospital has launched a Phase I dose-escalation study for PAN-NeoVax, an AI-designed pan-cancer neoantigen mRNA vaccine delivered via intratumoral injection. The trial targets advanced solid tumors post-second-line therapy, utilizing a 3+3 design to assess safety and preliminary efficacy of lipid nanoparticle-formulated mRNA.

clinicaltrials · brief 2026-05-29 · published 2026-05-11